Alpha-Linolenic Acid Treatment Reduces the Contusion and Prevents the Development of Anxiety-Like Behavior Induced by a Mild Traumatic Brain Injury in Rats

  • Taiza H. Figueiredo
  • Carolina L. Harbert
  • Volodymyr Pidoplichko
  • Camila P. Almeida-Suhett
  • Hongna Pan
  • Katia Rossetti
  • Maria F. M. Braga
  • Ann M. Marini
Article

Abstract

Approximately, 1.7 million Americans suffer a TBI annually and TBI is a major cause of death and disability. The majority of the TBI cases are of the mild type and while most patients recover completely from mild TBI (mTBI) about 10% result in persistent symptoms and some result in lifelong disability. Anxiety disorders are the second most common diagnosis post-TBI. Of note, TBI-induced anxiety disorders are difficult to treat and remain a chronic condition suggesting that new therapies are needed. Previous work from our laboratory demonstrated that a mild TBI induced an anxiety-like phenotype, a key feature of the human condition, associated with loss of GABAergic interneurons and hyperexcitability in the basolateral amygdala (BLA) in rodents 7 and 30 days after a controlled cortical impact (CCI) injury. We now confirm that animals display significantly increased anxiety-like behavior 30 days after CCI. The anxiety-like behavior was associated with a significant loss of GABAergic interneurons and significant reductions in the frequency and amplitude of spontaneous and miniature GABAA-receptor-mediated inhibitory postsynaptic currents (IPSCs) in the BLA. Significantly, subchronic treatment with alpha-linolenic acid (ALA) after CCI prevents the development of anxiety-like behavior, the loss of GABAergic interneurons, hyperexcitability in the BLA and reduces the impact injury. Taken together, administration of ALA after CCI is a potent therapy against the neuropathology and pathophysiological effects of mTBI in the BLA.

Keywords

Traumatic brain injury Anxiety disorders Controlled cortical impact Rat Alpha-linolenic acid 

References

  1. 1.
    Faul M, Xu L, Wald MM, Coronado V, Dellinger AM (2010) Traumatic brain injury in the United States: national estimates of prevalence and incidence, 2002-2006. Injury Prev 16:A268. doi:https://doi.org/10.1136/ip.2010.029215.951
  2. 2.
    Ma VY, Chan L, Carruthers KJ (2014) The incidence, prevalence, costs and impact on disability of common conditions requiring rehabilitation in the US: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss and back pain. Arch Phys Med Rehabil 95:986–995CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bigler ED, Maxwell WL (2012) Neuropathology of mild traumatic brain injury: relationship to neuroimaging findings. Brain Imaging Behav 6:108–136CrossRefPubMedGoogle Scholar
  4. 4.
    Wagner AK, Postal BA, Darrah SD, Chen X, Ljam AS (2007) Deficits in novelty exploration after controlled cortical impact. J Neurotrauma 24:1308–1320CrossRefPubMedGoogle Scholar
  5. 5.
    Sosin DM, Sniezek JE, Thurman DJ (1996) Incidence of mild and moderate brain injury in the United States, 1991. Brain Inj 10:47–54CrossRefPubMedGoogle Scholar
  6. 6.
    Kelly JP, Rosenberg JH (1997) Diagnosis and management of concussion in sports. Neurology 48:575–580CrossRefPubMedGoogle Scholar
  7. 7.
    McAllister TW, Flashman LA, McDonald BC, Saykin AJ (2006) Mechanisms of working memory dysfunction after mild and moderate TBI: Evidence from functional MRI and neurogenetics. J Neurotrauma 23:1450–1467CrossRefPubMedGoogle Scholar
  8. 8.
    Bay EH, Liberzon I (2009) Early stress response: a vulnerability framework for functional impairment following mild traumatic brain injury. Res Theory Nurs Pract 23:42–61CrossRefPubMedGoogle Scholar
  9. 9.
    Kennedy JE, Jaffee MS, Leskin GA, Stokes JW, Leal FO, Fitzpatrick PJ (2007) Posttraumatic stress disorder and posttraumatic stress disorder-like symptoms and mild traumatic brain injury. J Rehabil Res Dev 44:895–920CrossRefPubMedGoogle Scholar
  10. 10.
    Lewine JD, Davis JT, Bigler ED, Thoma R, Hill D, Funke M, Sloan JH, Hall S et al (2007) Objective documentation of traumatic brain injury subsequent to mild head trauma: multimodal brain imaging with MEG, SPECT, and MRI. J Head Trauma Rehabil 22:141–155CrossRefPubMedGoogle Scholar
  11. 11.
    Koponen S, Taiminen T, Portin R, Himanen L, Isoniemi H, Heinonen H, Hinkka S, Tenovuo O (2002) Axis I and II psychiatric disorders after traumatic brain injury: a 30-year follow-up study. Am J Psychiatry 159:1315–1321CrossRefPubMedGoogle Scholar
  12. 12.
    Hibbard HR, Uysal S, Kelpler K, Bogdany J, Silver J (1998) Axis I psychopathology in individuals with traumatic brain injury. J Head Trauma Rehabil 13:24–39CrossRefPubMedGoogle Scholar
  13. 13.
    Fann JR, Katon WJ, Uomoto JM, Esselman PC (1995) Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. Am J Psychiatry 152:1493–1499CrossRefPubMedGoogle Scholar
  14. 14.
    Zaninotto AL, Vicentini JE, Fregni F, Rodrigues PA, Botelho C, de Lucia MCS, Paiva WS (2016) Updates and current perspectives of psychiatric assessments after traumatic brain injury: a systematic review. Front Psychiatry 7:95. doi:https://doi.org/10.3389/fpsyt.2016.00095
  15. 15.
    Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA (2008) Mild traumatic brain injury in U.S. soldiers returning from Iraq. N Engl J Med 358:453–463CrossRefGoogle Scholar
  16. 16.
    Epstein RS, Ursano RJ (1994) Anxiety disorders. In: Silver JM, Yudofsky SC, Hales RE (eds) Neuropsychiatry of traumatic brain injury. American Psychiatric Press, Washington, D.C., pp. 285–311Google Scholar
  17. 17.
    Hiott DW, Labbate L (2002) Anxiety disorders associated with traumatic brain injuries. NeuroRehabilitation 17:345–355PubMedGoogle Scholar
  18. 18.
    Whelan-Goodison R, Ponsford J, Johnston L, Grant F (2009) Psychiatric disorders following traumatic brain injury: Their nature and frequency. J Head Trauma Rehabil 24:324–332CrossRefGoogle Scholar
  19. 19.
    Bryant RA (2008) Disentangling mild traumatic brain injury and stress reactions. N Engl J Med 358:525–527CrossRefPubMedGoogle Scholar
  20. 20.
    Holzschneider K, Mulert C (2011) Neurimaging in anxiety disorders. Dialogues Clin Neurosci 13:453–461PubMedPubMedCentralGoogle Scholar
  21. 21.
    Matthews SC, Strigo IA, Simmons AN, O’Connell RM, Reinhardt LE, Moseley SA (2011) A multimodal imaging study in U.S. veterans of operations Iraqi and enduring freedom with and without major depression after blast-related concussion. Neuroimage 54(Suppl 1):S69–S75. doi:https://doi.org/10.1016/j.neuroimage.2010.04.269
  22. 22.
    Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G et al (2000) Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 71(1 Suppl):179S–188SGoogle Scholar
  23. 23.
    Simopoulos AP, Leaf A, Salem N Jr (1999) Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab 43:127–130CrossRefPubMedGoogle Scholar
  24. 24.
    Owren PA, Hellem AJ, Odegaard A (1964) Linolenic acid for the prevention of thrombosis and myocardial infarction. Lancet 2(7367):975–978CrossRefPubMedGoogle Scholar
  25. 25.
    Holman RG, Johnson SB, Hatch TF (1982) A case of human linolenic acid deficiency involving neurological abnormalities. Am J Clin Nutr 35:617–623PubMedGoogle Scholar
  26. 26.
    Sanders TAB, Roshanai F (1983) The influence of different types of omega-3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers. Clin Sci 64:91–99CrossRefPubMedGoogle Scholar
  27. 27.
    Singer P, Berger I, Wirth M (1986) Slow desaturation and elongation of linoleic and alpha-linolenic acid as a rationale of eicosapentaenoic acid-rich diet to lower blood pressure and serum lipids in normal hypertensive patients and hyperlipidemic subjects. Prostaglandins Leukot Med 24:173–193CrossRefPubMedGoogle Scholar
  28. 28.
    Singer P, Jaeger W, Voigt S (1984) Defective desaturation and elongation on n-6 and n-3 fatty acids in hypertensive patients. Prostaglandins Leukot Med 15:159–165CrossRefPubMedGoogle Scholar
  29. 29.
    Adam O, Wolfram G, Zollner N (1986) Effect of alpha-linolenic acid in the human diet on linoleic acid metabolism and prostaglandin metabolism. J Lipid Res 27:421–426Google Scholar
  30. 30.
    Cunnane SC, Ganguli S, Menard C, Liede A, Hamadeh MJ, Chen Z-Y, Wolever TMS, Jenkins DJA (1993) High α-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans. Br J Nutr 69:443–453CrossRefPubMedGoogle Scholar
  31. 31.
    Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr (2001) Physiological compartmental analysis of α-linolenic acid metabolism in adult humans. J Lipid Res 42:1257–1265PubMedGoogle Scholar
  32. 32.
    Anding RH, Hwang DH (1986) Effects of dietary linolenate on the fatty acid composition of brain lipids in rats. Lipids 21(11):697–701CrossRefPubMedGoogle Scholar
  33. 33.
    Lin YH, Salem N Jr (2007) Whole body distribution of deuterated linoleic and α-linolenic acids and their metabolites in the rat. J Lipid Res 48:2709–2724CrossRefPubMedGoogle Scholar
  34. 34.
    Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M (2000) Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 19:1784–1793CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Blondeau N, Widmann C, Lazdunski M, Heurteaux C (2001) Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci 21:4668–4677PubMedGoogle Scholar
  36. 36.
    Marini AM, Jiang X, Wu X, Pan H, Guo Z, Mattson MP, Blondeau N, Novelli A et al (2007) Preconditioning and neurotrophins: a model for brain adaptation to seizures, ischemia and other stressful stimuli. Amino Acids 32:299–304CrossRefPubMedGoogle Scholar
  37. 37.
    Pan H, Hu XZ, Jacobowitz DM, Chen C, McDonough J, Van Shura K, Lyman M, Marini AM (2012) Alpha-linolenic acid is a potent neuroprotective agent against soman-induced neuropathology. Neurotoxicology 33:1219–1229CrossRefPubMedGoogle Scholar
  38. 38.
    Schmitz ML, Baeuerle PA (1991) The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J 10:3805–3817PubMedPubMedCentralGoogle Scholar
  39. 39.
    Lipsky RH, Xu K, Zhu D, Kelly C, Terhakopian A, Novelli A, Marini AM (2001) Nuclear factor kappaB is a critical determinant in N-methyl-D-aspartate receptor-mediated neuroprotection. J Neurochem 78:254–264CrossRefPubMedGoogle Scholar
  40. 40.
    Jiang X, Tian F, Du Y, Copeland NG, Jenkins NA, Tessarollo L, Wu X, Pan H et al (2008) BHLHB2 controls Bdnf promoter 4 activity and neuronal excitability. J Neurosci 28:1118–1130CrossRefPubMedGoogle Scholar
  41. 41.
    Blondeau N (2016) The nutraceutical potential of omega-3 alpha-linolenic acid in reducing the consequences of stroke. Biochimie 120:49–55CrossRefGoogle Scholar
  42. 42.
    Sala-Vila A, Guasch-Ferré M, Hu FB, Sánchez-Tainta A et al (2016) Dietary α-linolenic acid, marine ω-3 fatty acids, and mortality in a population with high fish consumption: findings from the PREvención con DIeta MEDiterránea (PREDIMED) study. J Am Heart Assoc 5(1):e002543. doi:https://doi.org/10.1161/JAHA.115.002543
  43. 43.
    Blondeau N, Lipsky RH, Bourourou M, Duncan MW, Gorelick PB, Marini AM (2015) Alpha-linolenic acid: an omega-3 fatty acid with neuroprotective properties-ready for use in the stroke clinic? Biomed Res Int 2015:519830. doi:https://doi.org/10.1155/2015/519830
  44. 44.
    Virtanen JK, Siscovick DS, Lemaitre RN, Longstreth WT, Spiegelman D, Rimm EB, King IB, Mozaffarian D (2013) Circulating omega-3 polyunsaturated fatty acids and subclinical brain abnormalities on MRI in older adults: the cardiovascular health study. J Am Heart Assoc 2(5):e000305. doi:https://doi.org/10.1161/JAHA.113.000305
  45. 45.
    de Goede J, Verschuren WM, Boer JM, Kromhout D, Geleijnse JM (2011) Alpha-linolenic acid intake and 10-year incidence of coronary heart disease and stroke in 20,000 middle-aged men and women in the Netherlands. PLoS One 6(3):e17967. doi:https://doi.org/10.1371/journal.pone.0017967
  46. 46.
    Lang-Lazdunski L, Blondeau N, Jarretou G, Lazdunski M, Heurteaux C (2003) Linolenic acid prevents neuronal cell death and paraplegia after transient spinal cord ischemia in rats. J Vasc Surg 38:564–575CrossRefPubMedGoogle Scholar
  47. 47.
    Heurteaux C, Laigle C, Blondeau N, Jarretou G, Lazdunski M (2006) Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 137:241–251CrossRefPubMedGoogle Scholar
  48. 48.
    Blondeau N, Nguemeni C, Debruyne DN, Piens M, Wu X, Pan H, Hu X, Gandin C et al (2009) Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: a versatile potential therapy for stroke. Neuropsychopharmacology 34:2548–2559CrossRefPubMedGoogle Scholar
  49. 49.
    Nguemeni C, Delplanque B, Rovère C, Simon-Rousseau N, Gandin C, Agnani G, Nahon JL, Heurteaux C et al (2010) Dietary supplementation of alpha-linolenic acid in an enriched rapeseed oil diet protects from stroke. Pharmacol Res 61:226–233CrossRefGoogle Scholar
  50. 50.
    Bourourou M, Heurteaux C, Blondeau N (2016) Alpha-linolenic acid given as enteral or parenteral nutritional intervention against sensorimotor and cognitive deficits in a mouse model of ischemic stroke. Neuropharmacology 108:60–72CrossRefPubMedGoogle Scholar
  51. 51.
    Piermartiri TC, Pan H, Chen J, McDonough J, Grunberg N, Apland JP, Marini AM (2015) Alpha-linolenic acid-induced increase in neurogenesis is a key factor in the improvement in the passive avoidance task after Soman exposure. NeuroMolecular Med 17:251–269CrossRefGoogle Scholar
  52. 52.
    Pan H, Piermartiri TC, Chen J, McDonough J, Oppel C, Driwech W, Winter K, McFarland E et al (2015) Repeated systemic administration of the nutraceutical alpha-linolenic acid exerts neuroprotective efficacy, an antidepressant effect and improves cognitive performance when given after soman exposure. Neurotoxicology 51:38–50CrossRefPubMedGoogle Scholar
  53. 53.
    Piermartiri T, Pan H, Figueiredo TH, Marini AM (2015) α-Linolenic acid, a nutraceutical with pleiotropic properties that targets endogenous neuroprotective pathways to protect against organophosphate nerve agent-induced neuropathology. Molecules 20(11):20355–20380. doi:https://doi.org/10.3390/molecules201119698
  54. 54.
    Desai A, Park T, Barnes J, Kevala K, Chen H, Kim HY (2016) Reduced acute neuroinflammation and improved functional recovery after traumatic brain injury by α-linolenic acid supplementation in mice. J Neuroinflammation 13:253CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Almeida-Suhett CP, Prager EM, Pidoplichko V, Figueiredo TH, Marini AM, Li Z, Eiden LE, Braga MF (2014) Reduced GABAergic inhibition in the basolateral amygdala and the development of anxiety-like behaviors after mild traumatic brain injury. PLoS One. doi:https://doi.org/10.1371/journal.pone.0102627
  56. 56.
    Prager EM, Bergstrom HC, Grunberg NE, Johnson LR (2011) The importance of reporting housing and husbandry in rat research. Front Behav Neurosci 5:38CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Lighthall JW (1988) Controlled cortical impact: A new experimental brain injury model. J Neurotrauma 5:1–15CrossRefPubMedGoogle Scholar
  58. 58.
    Almeida-Suhett CP, Li Z, Marini AM, Braga MF, Eiden LE (2014) Temporal course of changes in gene expression suggests a cytokine-related mechanism for long-term hippocampal alteration after controlled cortical impact. J Neurotrauma 31:683–690CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Faraday MM, Elliott BM, Grunberg NE (2001) Adult vs. adolescent rats differ in biobehavioral responses to chronic nicotine administration. Pharmacol Biochem Behav 70:475–489CrossRefPubMedGoogle Scholar
  60. 60.
    Aroniadou-Anderjaska V, Pidoplichko VI, Figueiredo TH, Almeida-Suhett CP, Prager EM, Braga MF (2012) Presynaptic facilitation of glutamate release in the basolateral amygdala: a mechanism for the anxiogenic and seizurogenic function of GluK1 receptors. Neuroscience 221:157–169CrossRefPubMedCentralGoogle Scholar
  61. 61.
    Figueiredo TH, Aroniadou-Anderjaska V, Qashu F, Apland JP, Pidoplichko V, Stevens D, Ferrara TM, Braga MF (2011) Neuroprotective efficacy of caramiphen against soman and mechanisms of its action. Br J Pharmacol 164:1495–1505CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF (2011) The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther 336:303–312CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B et al (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96:379–394CrossRefPubMedGoogle Scholar
  64. 64.
    Paxinos G, Watson C (2005) The rat brain in sterotaxic coordinates. Academic PressGoogle Scholar
  65. 65.
    Gundersen HJ, Jensen EB, Kieu K, Nielsen J (1999) The efficiency of systematic sampling in stereology—reconsidered. J Microsc 193:199–211CrossRefPubMedGoogle Scholar
  66. 66.
    Park K, Lee S, Kang SJ, Choi S, Shin KS (2007) Hyperpolarization-activated currents control the excitability of principal neurons in the basolateral amygdala. Biochem Biophys Res Commun 361:718–724CrossRefPubMedGoogle Scholar
  67. 67.
    Sah P, Faber ES, Lopez De Armentia M, Power J (2003) The amygdaloid complex: anatomy and physiology. Physiol Rev 83:803–834CrossRefPubMedGoogle Scholar
  68. 68.
    Andriessen TMJC, Horn J, Franschman G, van der Naalt J, Haitsma I, Jacobs B, Steyerberg EW, Vos PE (2011) Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury: a prospective multicenter study. J Neurotrauma 28:2019–2013CrossRefPubMedGoogle Scholar
  69. 69.
    Loane DJ, Stoica BA, Faden AI (2015) Neuroprotection for traumatic brain injury. Handb Clin Neurol 127:343–366CrossRefPubMedCentralGoogle Scholar
  70. 70.
    Loane DJ, Kumar A (2016) Microglia in the TBI brain: the good, the bad and the dysregulated. Exp Neurol 275:316–327CrossRefPubMedGoogle Scholar
  71. 71.
    Pidoplichko VI, Prager EM, Aroniadou-Anderjaska V, Braga MF (2013) α-7-containing nicotinic acetylcholine receptors on interneurons of the basolateral amygdala and their role in the regulation of network excitability. J Neurophysiol 110:2358–2369CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Basiouni S, Stockel K, Fuhrmann H, Schumann J (2012) Polyunsaturated fatty acids and supplements modulate mast cell membrane microdomain composition. Cell Immunol 275:42–46CrossRefPubMedGoogle Scholar
  73. 73.
    Simons K, Toomre D (2000) Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31–39CrossRefGoogle Scholar
  74. 74.
    Egawa J, Pearn ML, Lemkuil BP, Patel PM, Head BP (2016) Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function. J Physiol 594:4565–4579CrossRefPubMedGoogle Scholar
  75. 75.
    Mutoh T, Hamano T, Tokuda A, Kuriyama M (2000) Unglycosylated Trk protein does not co-localize with ganglioside GM1 in stable clone of PC12 cells overexpressing Trk (PCtrk cells). Glycoconj J 17:233–237CrossRefPubMedGoogle Scholar
  76. 76.
    Golub T, Wacha S, Caroni P (2004) Spatial and temporal control of signaling through lipid rafts. Curr Opin Neurobiol 14:542–550CrossRefPubMedGoogle Scholar
  77. 77.
    Besshoh S, Chen S, Brown IR, Gurd JW (2007) Developmental changes in the association of NMDA receptors with lipid rafts. J Neurosci Res 85:1876–1883CrossRefPubMedGoogle Scholar
  78. 78.
    Marini AM, Rabin SJ, Lipsky RH, Mocchetti I (1998) Activity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-D-aspartate. J Biol Chem 273:29394–29399CrossRefPubMedGoogle Scholar
  79. 79.
    Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20:709–726CrossRefPubMedGoogle Scholar
  80. 80.
    Prince DA, Gu F, Parada I (2016) Antiepileptogenic repair of excitatory and inhibitory synaptic connectivity after neocortical trauma. Prog Brain Res 226:209–227CrossRefPubMedGoogle Scholar
  81. 81.
    Ikonomidou C, Turski L (2002) Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 1:383–386CrossRefPubMedGoogle Scholar
  82. 82.
    Hung HC, Hsiao YH, Gean PW (2015) Sonic hedgehog signaling regulates amygdalar neurogenesis and extinction of fear memory. Eur Neuropsychopharmacol 25:1723–1732CrossRefPubMedGoogle Scholar
  83. 83.
    Jennett B (1996) Epidemiology of head injury. J Neurol Neurosurg Psychiatry 60:362–369CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Deb S, Lyons I, Koutzoukis C, Ali I, McCarthy G (1999) Rate of psychiatric illness 1 year after traumatic brain injury. Am J Psychiatry 156:374–378PubMedGoogle Scholar
  85. 85.
    MacMillan PJ, Hart RP, Martelli MF, Zasler ND (2002) Pre-injury status and adaptation following traumatic brain injury. Brain Inj 16:41–49CrossRefPubMedGoogle Scholar

Copyright information

© US Government (outside the USA) 2017

Authors and Affiliations

  • Taiza H. Figueiredo
    • 1
  • Carolina L. Harbert
    • 1
  • Volodymyr Pidoplichko
    • 1
  • Camila P. Almeida-Suhett
    • 1
  • Hongna Pan
    • 2
  • Katia Rossetti
    • 1
  • Maria F. M. Braga
    • 1
  • Ann M. Marini
    • 2
  1. 1.Department of Anatomy, Physiology and GeneticsUniformed Services University of the Health SciencesBethesdaUSA
  2. 2.Department of Neurology and Program in NeuroscienceUniformed Services University of the Health SciencesBethesdaUSA

Personalised recommendations